PD 2244

Drug Profile

PD 2244

Alternative Names: PD-2244

Latest Information Update: 21 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator P2D Bioscience
  • Class Anti-inflammatories; Antidementias
  • Mechanism of Action Interleukin 10 modulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Dementia

Most Recent Events

  • 21 Jul 2016 Preclinical trials in Alzheimer's disease in USA (PO)
  • 21 Jul 2016 Preclinical trials in Dementia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top